Works matching DE "OSIMERTINIB"
Results: 308
From ICU to long survival.
- Published in:
- Oncolog-Hematolog, 2024, v. 69, n. 4, p. 37
- By:
- Publication type:
- Article
Prolonged survival in EGFR-mutant lung adenocarcinoma: the power of targeted and combination therapies.
- Published in:
- Oncolog-Hematolog, 2024, v. 69, n. 4, p. 33
- By:
- Publication type:
- Article
EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non‐small cell lung cancer patients.
- Published in:
- Clinical & Translational Medicine, 2020, v. 9, n. 1, p. 1, doi. 10.1186/s40169-020-0269-y
- By:
- Publication type:
- Article
Treatment decision for recurrences in non-small cell lung cancer during or after adjuvant osimertinib: an international Delphi consensus report.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1330468
- By:
- Publication type:
- Article
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2023.1308460
- By:
- Publication type:
- Article
Case Report: Termination of unplanned pregnancy led to rapid deterioration of non-small-cell lung cancer during osimertinib treatment.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1073938
- By:
- Publication type:
- Article
Osimertinib inhibits brain metastases and improves long-term survival in a patient with advanced squamous cell lung cancer: a case report and literatures review.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1188772
- By:
- Publication type:
- Article
Case Report: Durable therapy response to Osimertinib in rare EGFR Exon 18 mutated NSCLC.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1182391
- By:
- Publication type:
- Article
Long-lasting benefit on multimodal treatment combining osimertinib and stereotaxic radiotherapy for metastatic non-small cell lung cancer with the EGFR exon 20 insertion 773-774 HVdelinsLM: a case report.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1143775
- By:
- Publication type:
- Article
Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1236311
- Publication type:
- Article
Case report: Osimertinib administration during pregnancy in a woman with advanced EGFR-mutant non-small cell lung cancer.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1108124
- By:
- Publication type:
- Article
Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1124949
- By:
- Publication type:
- Article
Case report: Identification of acute promyelocytic leukemia during osimertinib resistance followed by granulocyte colony-stimulating factor and pembrolizumab.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 01, doi. 10.3389/fonc.2022.1032225
- By:
- Publication type:
- Article
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
- Published in:
- Lung Cancer: Targets & Therapy, 2024, v. 15, p. 41, doi. 10.2147/LCTT.S453974
- By:
- Publication type:
- Article
Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib.
- Published in:
- Lung Cancer: Targets & Therapy, 2023, v. 14, p. 79, doi. 10.2147/LCTT.S431252
- By:
- Publication type:
- Article
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib.
- Published in:
- Lung Cancer: Targets & Therapy, 2022, v. 13, p. 23, doi. 10.2147/LCTT.S358902
- By:
- Publication type:
- Article
Exploring the impact of patient‐specific clinical features on osimertinib effectiveness in a real‐world cohort of patients with EGFR mutated non‐small cell lung cancer.
- Published in:
- International Journal of Cancer, 2024, v. 154, n. 2, p. 332, doi. 10.1002/ijc.34742
- By:
- Publication type:
- Article
Overall survival benefit of osimertinib and clinical value of upfront cranial local therapy in untreated EGFR‐mutant nonsmall cell lung cancer with brain metastasis.
- Published in:
- International Journal of Cancer, 2022, v. 150, n. 8, p. 1318, doi. 10.1002/ijc.33904
- By:
- Publication type:
- Article
Phase 1b trial of anti-EGFR antibody JMT101 and Osimertinib in EGFR exon 20 insertion-positive non-small-cell lung cancer.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-39139-4
- By:
- Publication type:
- Article
Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancer.
- Published in:
- Nature Communications, 2022, v. 13, n. 1, p. 1, doi. 10.1038/s41467-022-34889-z
- By:
- Publication type:
- Article
Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Crystal structure of osimertinib mesylate Form B (Tagrisso), (C<sub>28</sub>H<sub>34</sub>N<sub>7</sub>O<sub>2</sub>)(CH<sub>3</sub>O<sub>3</sub>S).
- Published in:
- Powder Diffraction, 2021, v. 36, n. 4, p. 282, doi. 10.1017/S0885715621000555
- By:
- Publication type:
- Article
Afatinib or Bevacizumab in combination with Osimertinib efficiently control tumor development in orthotopic murine models of non-small lung cancer.
- Published in:
- PLoS ONE, 2024, v. 19, n. 6, p. 1, doi. 10.1371/journal.pone.0304914
- By:
- Publication type:
- Article
Real-world osimertinib pretreatment experience in patients with epidermal growth factor receptor T790M mutation-positive locally advanced or metastatic non-small cell lung cancer.
- Published in:
- PLoS ONE, 2024, v. 19, n. 5, p. 1, doi. 10.1371/journal.pone.0303046
- By:
- Publication type:
- Article
Thermal treatment decreases resistance to osimertinib in non-small cell lung cancer through the EGFR/PI3K/AKT pathway.
- Published in:
- Neoplasma, 2021, v. 68, n. 3, p. 535, doi. 10.4149/neo_2021_200506N489
- By:
- Publication type:
- Article
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
The Effects of a Curcumin Derivative and Osimertinib on Fatty Acyl Metabolism and Mitochondrial Functions in HCC827 Cells and Tumors.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 15, p. 12190, doi. 10.3390/ijms241512190
- By:
- Publication type:
- Article
TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma.
- Published in:
- International Journal of Molecular Sciences, 2022, v. 23, n. 18, p. N.PAG, doi. 10.3390/ijms231810415
- By:
- Publication type:
- Article
Acquired Resistance to Osimertinib in EGFR -Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
- Published in:
- 2022
- By:
- Publication type:
- Literature Review
EphB4 as a Novel Target for the EGFR-Independent Suppressive Effects of Osimertinib on Cell Cycle Progression in Non-Small Cell Lung Cancer.
- Published in:
- International Journal of Molecular Sciences, 2021, v. 22, n. 16, p. 8522, doi. 10.3390/ijms22168522
- By:
- Publication type:
- Article
Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer.
- Published in:
- BMC Medicine, 2024, v. 22, n. 1, p. 1, doi. 10.1186/s12916-024-03389-w
- By:
- Publication type:
- Article
Osteoblastic bone reaction in non-small cell lung cancer harboring epidermal growth factor receptor mutation treated with osimertinib.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11360-w
- By:
- Publication type:
- Article
Afatinib plus osimertinib in the treatment of osimertinib-resistant non-small cell lung carcinoma: a phase I clinical trial.
- Published in:
- BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-022-10467-w
- By:
- Publication type:
- Article
Rationale and protocol design of a phase II study of first-line osimertinib treatment for patients with poor performance status and EGFR mutation-positive non-small cell lung cancer (OPEN/TORG2040).
- Published in:
- BMC Cancer, 2022, v. 22, n. 1, p. 1, doi. 10.1186/s12885-022-10409-6
- By:
- Publication type:
- Article
Safety of osimertinib in adult patients with metastatic epidermal growth factor receptor T790M mutation‑positive non‑small cell lung cancer: Results from a Phase IV study in India.
- Published in:
- Indian Journal of Cancer, 2022, v. 59, p. S1, doi. 10.4103/ijc.ijc_1374_21
- By:
- Publication type:
- Article
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib.
- Published in:
- Communications Biology, 2023, v. 6, n. 1, p. 1, doi. 10.1038/s42003-023-04889-w
- By:
- Publication type:
- Article
Tagrisso Approved as Adjuvant Therapy for NSCLC with EGFR Mutations.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 1, p. 11
- Publication type:
- Article
Osimertinib Approved for Stage III Non-Small Cell Lung Cancer Following Chemo.
- Published in:
- Oncology Practice Management, 2024, v. 14, n. 11, p. 15
- Publication type:
- Article
Expert opinion on adjuvant treatment with osimertinib in patients with non-small cell lung carcinoma after radical tumor resection.
- Published in:
- Nowotwory, 2023, v. 73, n. 3, p. 187, doi. 10.5603/njo.96212
- By:
- Publication type:
- Article
Real-World Data on Osimertinib-Associated Cardiac Toxicity.
- Published in:
- Journal of Clinical Medicine, 2025, v. 14, n. 5, p. 1754, doi. 10.3390/jcm14051754
- By:
- Publication type:
- Article
A Case of Rapidly Progressive Diabetic Nephropathy Induced by Osimertinib.
- Published in:
- 2023
- By:
- Publication type:
- Case Study
Integrating network pharmacology and experimental validation to explore the potential mechanism by which resveratrol acts on osimertinib resistance in lung cancer.
- Published in:
- Oncology Letters, 2025, v. 29, n. 4, p. N.PAG, doi. 10.3892/ol.2025.14938
- By:
- Publication type:
- Article
Osimertinib treatment response in a patient with lung adenocarcinoma harboring two rare EGFR mutations: A case report.
- Published in:
- Oncology Letters, 2024, v. 28, n. 5, p. 1, doi. 10.3892/ol.2024.14634
- By:
- Publication type:
- Article
Upregulation of long non‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib.
- Published in:
- Oncology Letters, 2023, v. 26, n. 3, p. N.PAG, doi. 10.3892/ol.2023.13966
- By:
- Publication type:
- Article
Aumolertinib challenge as an optional treatment in advanced non small-cell lung cancer after osimertinib failure with epidermal growth factor receptor-sensitive mutation: A case series.
- Published in:
- 2022
- By:
- Publication type:
- Case Study
Triple therapy with osimertinib, bevacizumab and cetuximab in EGFR-mutant lung cancer with HIF-1α/TGF-α expression.
- Published in:
- Oncology Letters, 2021, v. 22, n. 3, p. N.PAG, doi. 10.3892/ol.2021.12900
- By:
- Publication type:
- Article
Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis.
- Published in:
- Oncology Letters, 2020, v. 20, n. 3, p. 2266, doi. 10.3892/ol.2020.11801
- By:
- Publication type:
- Article
Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.733276
- By:
- Publication type:
- Article